Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 10/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3915405 | 0.87 | PIM1 (0.37) | GPR6KDM4CMAP3K7PIM2PIM3 | |
| SCHEMBL3903799 | 0.86 | TXK (0.39) | GPR6PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8286962 | 0.82 | ATR (0.39) | GPR6GSK3BGSK3APDE4APDE4B | |
| Trifluoroacetic Acid SCHEMBL3904243 | 0.80 | PIM1 (0.37) | GPR6KDM4CPDE4APDE4BPDE4C | |
| SCHEMBL3904985 | 0.77 | MAPT (0.42) | MAPT | |
| SCHEMBL3905636 | 0.77 | GPR6 (0.41) | GPR6GSK3BGSK3APDE4APDE4B | |
| SCHEMBL3903857 | 0.75 | TBK1 (0.40) | GPR6PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8287702 | 0.74 | PTGDR (0.40) | GPR6PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3158995 | 0.73 | F10 (0.47) | — | |
| SCHEMBL3904310 | 0.72 | TOP2A (0.40) | GPR6PDE4BPIM2PIM3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511066-B2 | Antithrombotic aromatic ethers | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20070027185-A1 | Antithrombotic aromatic ethers | ELILILLY AND COMPANY (US) | 2007-02-01 | — | — | US | disclosed |
| EP-1670783-A2 | ANTITHROMBOTIC AROMATIC ETHERS | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005049604-A2 | ANTITHROMBOTIC AROMATIC ETHERS | ELI LILLY AND COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027185-A1 | Antithrombotic aromatic ethers | F2, F11, TFPI | GPR6 2624/4885KDM4C 2278/4885GSK3B 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.